Building a roadmap to biomarker qualification: challenges and opportunities.

The traditional route for regulatory acceptance of biomarkers in drug development is through submission of biomarker data in drug approval submissions in the context of a single drug development program. The US FDA's Critical Path Initiative called for establishment of a biomarker qualification process to enable progress in the drug development paradigm. In response to this, the Center for Drug Evaluation and Research (CDER) established a Biomarker Qualification Program (BQP) to qualify a biomarker for a specific context of use (COU). The qualified biomarker can then be used in multiple drug development programs for this COU without re-review. Here, we describe some of the features of the BQP and two new initiatives that have the potential to aid biomarker development through early interactions with the FDA. Finally, we discuss some of the feedback the FDA has received from submitters and the BQP's actions to strengthen the program.

[1]  A. E. Hoerl,et al.  Ridge regression: biased estimation for nonorthogonal problems , 2000 .

[2]  Serafino Pantano,et al.  Urinary clusterin, cystatin C, β2-microglobulin and total protein as markers to detect drug-induced kidney injury , 2010, Nature Biotechnology.

[3]  I. Zineh,et al.  Qualifying biomarkers for use in drug development: a US Food and Drug Administration overview. , 2011, Expert opinion on medical diagnostics.

[4]  S. Amur,et al.  Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization , 2015, Clinical pharmacology and therapeutics.

[5]  Syril Pettit,et al.  Biological qualification of biomarkers of chemical-induced renal toxicity in two strains of male rat. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[6]  A. Szarfman,et al.  Qualification of cardiac troponins for nonclinical use: a regulatory perspective. , 2013, Regulatory toxicology and pharmacology : RTP.

[7]  D. DeMets,et al.  Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework , 2001, Clinical pharmacology and therapeutics.

[8]  S. Amur,et al.  Catalyzing the critical path initiative: FDA's progress in drug development activities , 2015, Clinical pharmacology and therapeutics.

[9]  Wesley O Johnson,et al.  Diagnosis using predictive probabilities without cut‐offs , 2006, Statistics in medicine.

[10]  Frank Bretz,et al.  Multiplicity and replicability: two sides of the same coin , 2014, Pharmaceutical statistics.

[11]  F. Frueh,et al.  Biomarker qualification pilot process at the US Food and Drug Administration , 2007, The AAPS Journal.

[12]  G. Ruaño,et al.  Retrospective validation of genomic biomarkers – what are the questions, challenges and strategies for developing useful relationships to clinical outcomes – workshop summary , 2006, The Pharmacogenomics Journal.

[13]  Krishna Prasad,et al.  Renal biomarker qualification submission: a dialog between the FDA-EMEA and Predictive Safety Testing Consortium , 2010, Nature Biotechnology.